Research Program: Transplant Biology & Therapy
Assistant Professor, Division of Hematology, Oncology, and Transplantation, Department of Medicine

tombl001@umn.edu
612-624-5109 — office
Preferred method of contact: e-mail

Dr. Tomblyn's clinical profile
(University of Minnesota Physicians Web site)

Dr. Tomblyn earned her medical degree at the University of Kentucky in 1997. She completed her internal medicine residency and a chief resident year at the University of Kentucky. She then completed a hematology/oncology fellowship and an additional year of training in hematopoietic stem cell transplantation at Northwestern University in 2004. She obtained a master of science degree in clinical investigation at Northwestern University in 2004. She is board certified in internal medicine, hematology, and oncology.

Research Interests

Dr. Tomblyn's clinical interest is the treatment of hematological malignancies using immunotherapy and stem cell transplantation. She has particular interests in lymphomas, immune reconstitution, post-transplant infections, and the supportive management of patients undergoing transplantation. She is active in both local and national clinical research. She serves as an assistant scientific director for the Center for International Blood and Marrow Transplant Research (CIBMTR) and is the director of the CIBMTR Resource for Clinical Investigation in Blood and Marrow Transplantation. She is an active member of the Data Coordinating Center of the NHLBI/NCI-funded Blood and Marrow Transplant Clinical Trials Network.

Selected Publications

Tomblyn, M, L Gordon, S Singhal, M Tallman, S Williams, J Winter, J Mehta. Rarity of toxigenic clostridium difficile after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant, 2002;30:517-519.

Tomblyn, M, M Tallman. New developments in antibody therapy for Acute Myeloid Leukemia. Semin Oncol; 2003;30:502-508.

Tomblyn, M, JN Winter. The role of hematopoietic growth factors as adjuncts to the treatment of Hodgkin's and non-Hodgkin's lymphomas. In: Morstyn G, MA Foote, G Lieschke, ed. Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics. Humana Press, 2003: 275-284.

Tomblyn, M, JN Winter. The Role of Autologous Hematopoietic Stem Cell Transplant in First Complete Remission in Patients with Non-Hodgkin's Lymphoma. Expert Rev Anticancer Ther. 2003;3:281-294.

Tomblyn, M, LI Gordon, S Singhal, MS Tallman, S Williams, JN Winter, J Mehta. Use of Total Leukocyte and Platelet Counts to Guide Stem Cell Apheresis in Healthy Allogeneic Donors Treated with G-CSF. Bone Marrow Transplant, 2005; 36 (8): 663-666.

Weisdorf, D, M Tomblyn. Management of the Bone Marrow Transplant Patient. In: Chang, AE, PA Ganz, DF hayes, TJ Kinsella, HI Pass, JH Schiller, RM Stone, VJ Strecher, ed. Oncology: An Evidence-Based Approach. Springer Science+Business Media, Inc., 2006

Hui, Susanta, MR Verneris, P Higgins, B Gerbi, B Weigel, S Baker, C Fraser, M Tomblyn, K Dusenbery. Helical Tomotherapy Targeting Total Bone Marrow—Initial Clinical Experience at the University of Minnesota. Acta Oncologica, 2007; 46 (2): 250-255.

Tomblyn, M, L Burns, B Blazar, J Wagner, C Lee, T Rogers, P McGlave, J Miller, D Weisdorf. Difficult Stem Cell Mobilization in Lymphoma Patients Predicts Shortened Progression Free and Overall Survival After Autologous HSCT Despite Adequate CD34+ Cell Dose. Bone Marrow Transplantation 2007; 11(2): 111- 118.

Tomblyn, M, JD Rizzo. Are There Circumstances in Which Phase 2 Study Results Should Be Practice-Changing? Hematology Am Soc Hematol Educ Program. 2007;2007:489-92

Majhail, NS, CG Brunstein, M Tomblyn, AJ Thomas, JE Wagner, M Arora, DS Kaufman, LJ Burns, JS Miller, A Slungaard, PB McGlave, DJ Weisdorf. Reduced-Intensity Allogeneic Transplantation in Patients Older than 55 Years: Unrelated Umbilical Cord Blood is Safe and Effective for Patients without a Matched Related Donor. Biology of Blood and Marrow Transplantation, 2008; 14 (3): 282 -289.

Tomblyn, M, C Brunstein, L Burns, J Miller, Y Tan, D Weisdorf. Equivalent Disease Free and Overall Survival in Lymphoma Patients Treated with either Myeloablative (MA) or Non-Myeloablative (NMA) Conditioning and Allogeneic Stem Cell Transplant (SCT). Biology of Blood and Marrow Transplantation, 2008; 14 (5): 538-545.

Bachanova, V, C Brunstein, L Burns, J Miller, Y Tan, D Weisdorf, M Tomblyn. Fewer early Bacterial and Viral Infections following Non-Myeloablative vs Myeloablative conditioning for Allotransplantation. Bone Marrow Transplantation (in press)

Tomblyn, M, K Dusenbery, M Tomblyn. Central nervous system relapse in acute promyelocytic leukemia: Two cases and a systematic review. Clinical Leukemia (in press).